新型潜在生物标志物在心房颤动血栓栓塞风险中的作用
Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.
作者信息
Pezzo Mario Piergiulio, Tufano Antonella, Franchini Massimo
机构信息
Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, 46100 Mantova, Italy.
Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
出版信息
J Clin Med. 2022 Feb 9;11(4):915. doi: 10.3390/jcm11040915.
Abstract
Ischemic stroke risk in atrial fibrillation differs from patient to patient, depending on numerous variables. Many attempts have been made to translate this difference into simple numbers and to compare it to the hemorrhagic risk of anticoagulation. Different clinical scores have been studied to define a clear strategy. One score, the CHADS-VASc score, has been extensively and successfully applied worldwide. Nevertheless, it is not yet the "perfect instrument". Many proposals have been made to integrate its clinical parameters with some biomarkers to improve its predictive power. This short review describes some of these biomarkers and their possible implications in potentiating the efficacy of clinical scores.
摘要
心房颤动患者的缺血性中风风险因人而异，取决于众多变量。人们已多次尝试将这种差异转化为简单数字，并与抗凝治疗的出血风险进行比较。为确定明确策略，已对不同的临床评分进行了研究。其中一个评分，即CHADS-VASc评分，已在全球广泛且成功应用。然而，它仍不是“完美工具”。人们已提出许多建议，将其临床参数与一些生物标志物相结合，以提高其预测能力。这篇简短综述介绍了其中一些生物标志物及其在增强临床评分疗效方面的可能意义。
相似文献
1
Role of New Potential Biomarkers in the Risk of Thromboembolism in Atrial Fibrillation.新型潜在生物标志物在心房颤动血栓栓塞风险中的作用
J Clin Med. 2022 Feb 9;11(4):915. doi: 10.3390/jcm11040915.
2
Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.评估 CHA2DS2-VASc 评分在伴有和不伴有心房颤动的心力衰竭患者中预测缺血性卒、血栓栓塞和死亡的价值。
JAMA. 2015 Sep 8;314(10):1030-8. doi: 10.1001/jama.2015.10725.
3
[The thromboembolism risk of low-risk atrial fibrillation patients with different clinical characteristics].[不同临床特征的低风险心房颤动患者的血栓栓塞风险]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Sep 24;48(9):735-739. doi: 10.3760/cma.j.cn112148-20200306-00164.
4
The ATRIA score is superior to the m-CHA2DS2-Vasc score in predicting in-hospital mortality in COVID-19.ATRIA 评分优于 m-CHA2DS2-Vasc 评分，可预测 COVID-19 患者住院期间的死亡率。
Rev Assoc Med Bras (1992). 2021 Mar;67(3):443-448. doi: 10.1590/1806-9282.20200983.
5
Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.CHADS2与CHA2DS2-VASc对心房颤动患者独立于抗凝治疗的中风和血栓栓塞预测的荟萃分析。
Tex Heart Inst J. 2015 Feb 1;42(1):6-15. doi: 10.14503/THIJ-14-4353. eCollection 2015 Feb.
6
Comparison between CHADS2 and CHA2DS2-VASc score for risk stratification of ischemic stroke in Japanese patients with non-valvular paroxysmal atrial fibrillation not receiving anticoagulant therapy.未接受抗凝治疗的日本非瓣膜性阵发性心房颤动患者缺血性卒中风险分层的CHADS2与CHA2DS2-VASc评分比较
Int Heart J. 2014;55(2):119-25. doi: 10.1536/ihj.13-242. Epub 2014 Mar 14.
7
Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.CHA2DS2-VASC 与 CHADS2 抗凝推荐的比较：在房颤消融患者队列中的评估。
Europace. 2014 Feb;16(2):195-201. doi: 10.1093/europace/eut244. Epub 2013 Sep 12.
8
Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis.房颤且 CHA2DS2-VASc 评分为 1 分的患者的缺血性卒中风险：系统评价和荟萃分析。
Stroke. 2016 May;47(5):1364-7. doi: 10.1161/STROKEAHA.115.012609. Epub 2016 Mar 29.
9
Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.验证改良 CHA2DS2-VASc 评分在亚洲房颤患者中风风险分层中的应用：一项全国性队列研究。
Stroke. 2016 Oct;47(10):2462-9. doi: 10.1161/STROKEAHA.116.013880. Epub 2016 Sep 13.
10
CHADS-VASc Score: A Predictor of Thromboembolic Events and Mortality in Patients With an Implantable Monitoring Device Without Atrial Fibrillation.CHADS-VASc评分：无房颤的植入式监测装置患者血栓栓塞事件和死亡率的预测指标
Mayo Clin Proc. 2017 Mar;92(3):360-369. doi: 10.1016/j.mayocp.2016.10.008.
引用本文的文献
1
Interpretable Independent Recurrent Networks for Forecasting Stroke in Atrial Fibrillation.用于预测心房颤动中风的可解释独立循环网络
JACC Asia. 2025 Aug;5(8):966-978. doi: 10.1016/j.jacasi.2025.04.003. Epub 2025 Jun 10.
2
Efficacy and Safety of New Oral Anticoagulants versus Warfarin in the Resolution of Atrial Fibrillation with Left Atrial/Left Atrial Appendage Thrombus: A Systematic Review and Meta-Analysis.新型口服抗凝药与华法林在心房颤动合并左心房/左心耳血栓溶解中的疗效与安全性：一项系统评价和荟萃分析
Rev Cardiovasc Med. 2025 Jan 20;26(1):26055. doi: 10.31083/RCM26055. eCollection 2025 Jan.
3
D-dimer and fibrinogen indicate ischemic risk in patients with atrial fibrillation after percutaneous coronary intervention.D-二聚体和纤维蛋白原提示经皮冠状动脉介入治疗后房颤患者的缺血风险。
Thromb J. 2024 May 21;22(1):42. doi: 10.1186/s12959-024-00610-x.
4
How we manage a high D-dimer.如何管理高 D-二聚体。
Haematologica. 2024 Apr 1;109(4):1035-1045. doi: 10.3324/haematol.2023.283966.
本文引用的文献
1
The Role of Galectin-3 and ST2 in Cardiology: A Short Review.半乳糖凝集素-3 和 ST2 在心脏病学中的作用：简要综述。
Biomolecules. 2021 Aug 7;11(8):1167. doi: 10.3390/biom11081167.
2
A Review of Biomarkers for Ischemic Stroke Evaluation in Patients With Non-valvular Atrial Fibrillation.非瓣膜性心房颤动患者缺血性卒中评估生物标志物综述
Front Cardiovasc Med. 2021 Jul 1;8:682538. doi: 10.3389/fcvm.2021.682538. eCollection 2021.
3
Atrial fibrillation and stroke prevention: state of the art-epidemiology and pathophysiology: new risk factors, concepts and controversies.心房颤动与卒中预防：最新进展——流行病学与病理生理学：新的危险因素、概念及争议
Eur Heart J Suppl. 2020 Dec 22;22(Suppl O):O1-O13. doi: 10.1093/eurheartj/suaa176. eCollection 2020 Dec.
4
Optimized stratification of risk factors in and beyond the CHA2DS2-VASc score to differentiate the real thromboembolic risk in mainland China: a systematic review and meta-analysis.优化CHA2DS2-VASc评分内外的危险因素分层以鉴别中国大陆真实的血栓栓塞风险：一项系统评价和Meta分析
Ann Palliat Med. 2020 Nov;9(6):4252-4261. doi: 10.21037/apm-20-297. Epub 2020 Nov 10.
5
LDL-C/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study.载脂蛋白 B/载脂蛋白 A1 与非瓣膜性心房颤动患者缺血性卒中的关系：病例对照研究。
Lipids Health Dis. 2020 Oct 7;19(1):217. doi: 10.1186/s12944-020-01392-7.
6
Serum uric acid and incident atrial fibrillation: A systematic review and dose-response meta-analysis.血清尿酸与心房颤动事件：系统评价和剂量反应荟萃分析。
Clin Exp Pharmacol Physiol. 2020 Nov;47(11):1774-1782. doi: 10.1111/1440-1681.13374. Epub 2020 Aug 6.
7
Mean platelet volume: a new predictor of ischaemic stroke risk in patients with nonvalvular atrial fibrillation.平均血小板体积：非瓣膜性心房颤动患者缺血性卒中风险的新预测指标。
BMC Cardiovasc Disord. 2020 May 20;20(1):241. doi: 10.1186/s12872-020-01525-x.
8
Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two-sample Mendelian randomization study.循环白细胞介素与冠状动脉疾病、心房颤动和缺血性卒中和其亚型的关系：一项两样本 Mendelian 随机研究。
Int J Cardiol. 2020 Aug 15;313:99-104. doi: 10.1016/j.ijcard.2020.03.053. Epub 2020 Mar 21.
9
Association Between High-Sensitivity Cardiac Troponin and Risk of Stroke in 96 702 Individuals: A Meta-Analysis.高敏心肌肌钙蛋白与 96702 例个体中风风险的关系：一项荟萃分析。
Stroke. 2020 Apr;51(4):1085-1093. doi: 10.1161/STROKEAHA.119.028323. Epub 2020 Feb 10.
10
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.评估房颤患者发生卒中或全身性栓塞及出血风险的 ABC 评分在 ENGAGE AF-TIMI 48 中的表现。
Circulation. 2019 Feb 5;139(6):760-771. doi: 10.1161/CIRCULATIONAHA.118.038312.
Zotero 插件